Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Design A 48-week randomised, double-blind, placebo-controlled trial
7.1 Bayesian perspective: turning evidence asymmetry into communicable probabilities The evidence base for GLP-1RAs in PCOS is asymmetric
They were then randomized to either continue tirzepatide or switch to placebo for another 52 weeks
This comparison covers what each drug actually does, what the trial data shows, how safety profiles compare, and what that gap means in clinical terms
US$ 24.94
US$ 22.85
US$ 21.72
US$ 24.61
US$ 24.87
US$ 28.13
US$ 27.47
